MENU
Showcases Stock ranks Forex

Aileron Therapeutics Inc (ALRN)
0.1999  0.028 (16.22%) 08-08 16:00
Open: 0.2083 Pre. Close: 0.172
High: 0.249 Low: 0.1855
Volume: 5,340,075 Market Cap: 18M
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.25 - 0.251 0.251 - 0.252
Low: 0.188 - 0.189 0.189 - 0.19
Close: 0.199 - 0.2 0.2 - 0.201
Stock Technical Analysis
Overall:     
Target: Six months: 0.28
One year: 0.35
Support: Support1: 0.13
Support2: 0.11
Resistance: Resistance1: 0.24
Resistance2: 0.30
Pivot: 0.19
Moving Averages: MA(5): 0.16
MA(20): 0.20
MA(100): 0.40
MA(250): 0.60
MACD: MACD(12,26): -0.04
Signal(12,26,9): -0.04
%K %D: %K(14,3): 36.80
%D(3): 23.48
RSI: RSI(14): 43.40
52-Week: High: 1.27
Low: 0.131
Change(%): -80.6
Average Vol(K): 3-Month: 679
10-Days: 2276
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ ALRN ] has closed below upper band by 37.9%. Bollinger Bands are 35.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Tue, 09 Aug 2022
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday - Benzinga

Mon, 08 Aug 2022
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session By Benzinga - Investing.com UK

Mon, 08 Aug 2022
Penny Stocks to Buy on August 8th? 3 to Watch - StreetInsider.com

Tue, 02 Aug 2022
Is Aileron Therapeutics Inc (ALRN) Stock About to Get Hot Tuesday? - InvestorsObserver

Thu, 19 May 2022
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer - GlobeNewswire

Tue, 10 May 2022
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology - GlobeNewswire

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 90.82
Shares Float (M) 60.75
% Held by Insiders 9.02
% Held by Institutions 35.37
Shares Short (K) 183
Shares Short Prior Month (K) 297
Stock Financials
EPS -0.305
Book Value (p.s.) 0.400
Profit Margin
Operating Margin
Return on Assets (ttm) -33.4
Return on Equity (ttm) -56.6
Qtrly Rev. Growth
Gross Profit (p.s.) -0.187
Sales Per Share
EBITDA (p.s.) -0.307
Qtrly Earnings Growth
Operating Cash Flow (M) -25.08
Levered Free Cash Flow (M) -14.70
Stock Valuation
PE Ratio -0.66
PEG Ratio -0.21
Price to Book value 0.50
Price to Sales
Price to Cash Flow -0.72
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android